v3.26.1

Net Loss Per Share | 6 Months Ended | 12 Months Ended
--- | --- | ---
Nov. 30, 2025 | Dec. 31, 2025 | May 31, 2025
Net Loss Per Share [Line Items] |  |  |
NET LOSS PER SHARE |  | 19. NET LOSS PER SHARE The following table sets forth the computation of basic and diluted loss per share:
|  | Year ended December 31, 2025 |  | Year ended December 31, 2024 |  | Year ended December 31, 2023
Numerator: |  |  |  |  |  |  |  |  |  |  |
Net loss attributable to Aptorum Group Limited |  | $ | (1,363,270 | ) |  | $ | (4,267,806 | ) |  | (2,824,647 | )
Denominator: |  |  |  |  |  |  |  |  |  |  |
Basic and diluted weighted average shares outstanding |  |  | 7,351,784 |  |  |  | 5,453,103 |  |  | 4,521,133 |
Net loss per share attributable to Aptorum Group Limited(1) |  |  |  |  |  |  |  |  |  |  |
Basic and diluted loss per share |  | $ | (0.19 | ) |  | $ | (0.78 | ) |  | (0.62 | )
Basic loss per share is computed by dividing net loss attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue ordinary shares were exercised or converted into ordinary shares. Potential dilutive securities are excluded from the calculation of diluted loss per share in loss periods as their effect would be anti-dilutive. For the year ended December 31, 2025, 2024 and 2023, the total number of share options, warrants and convertible notes excluded from the calculation of diluted earnings per share due to their anti-dilutive nature, are 3,452,457, 1,392,277 and 1,293,723, respectively. |
DiamiR Biosciences Corp. [Member] |  |  |
Net Loss Per Share [Line Items] |  |  |
NET LOSS PER SHARE | NOTE 12 — LOSS PER SHARE The following common stock equivalents have been excluded from the calculation of loss per share because their effects would be antidilutive in the nine months ended February 28:
|  | 2026 |  | 2025
Stock options |  | 441,750 |  | 511,950
Restricted stock |  | 88,000 |  | 88,000
Warrants |  | — |  | 29,336
Additional shares are issuable under the Company’s convertible notes, the amount of which is dependent on future events. |  | NOTE 13 — LOSS PER SHARE The following common stock equivalents have been excluded from the calculation of loss per share because their effects would be antidilutive:
|  | 2025 |  | 2024
Stock options |  | 511,950 |  | 511,950
Restricted stock |  | 88,000 |  | 88,000
Warrants |  | — |  | 29,336
Additional shares are issuable under the Company’s convertible notes, the amount of which is dependent on future events.

X
- References No definition available. + Details
Name: | apm_NetLossPerShareLineItems
Namespace Prefix: | apm_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=apm_DiamiRBiosciencesCorpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |